phenobarbital brand name philippines

Monitor for the possibility of reduced effectiveness of repaglinide and possible symptoms indicating hyperglycemia. Ceritinib is a CYP3A4 substrate and phenobarbital is a strong CYP3A4 inducer. Avoid concurrent use of Abilify Maintena with a CYP3A4 inducer when the combined treatment period exceeds 14 days because aripiprazole blood concentrations decline and may become suboptimal. Oxazepam: (Moderate) Additive CNS and/or respiratory depression may occur with concurrent use. (Major) Avoid coadministration of sofosbuvir with inducers of P-glycoprotein (P-gp), such as phenobarbital. Monitor for additive CNS and respiratory effects, and warn about the potential effects to driving and other activities. Limit the use of opioid pain medications with barbiturates to only patients for whom alternative treatment options are inadequate. Barbiturates may be associated with marked excitement, depression, or confusion in these patients. Discuss biotin status with patients taking these medications concomitantly. Monitor for signs of opioid withdrawal. Bismuth Subsalicylate: (Moderate) Due to high protein binding, salicylates could be displaced from binding sites, or could displace other highly protein-bound drugs such as barbiturates. You should confirm the information on the PDR.net site through independent sources and seek other professional guidance in all treatment and diagnosis decisions. Levomefolate: (Moderate) Numerous studies indicate that folate status is impaired with the chronic use of phenobarbital, presumably via inhibition of the intestinal absorption of folic acid. Fluticasone; Vilanterol: (Moderate) Coadministration may result in decreased exposure to fluticasone. Esterified Estrogens: (Moderate) Barbiturates can accelerate the hepatic clearance of estrogens. It is recommended to avoid this combination when hydrocodone is being used for cough. Dabrafenib: (Major) Use dabrafenib and phenobarbital together with caution; concentrations of either agent may be decreased. If large doses are used, monitor phenobarbital concentrations upon folic acid initiation, dose titration, and discontinuation. Progestins: (Moderate) Barbiturates can accelerate the hepatic clearance of progestins. Doravirine; Lamivudine; Tenofovir disoproxil fumarate: (Severe) Concurrent administration of doravirine and phenobarbital is contraindicated due to decreased doravirine exposure, resulting in potential loss of virologic control. Additionally, concomitant use of codeine with a barbiturate can decrease codeine concentrations, resulting in less metabolism by CYP2D6 and decreased morphine concentrations; this may result in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence. The mechanism of interaction is unclear; those proposed in the medical literature include increased indocyanine green uptake by the liver cell, enhanced binding by specific hepatic carrier proteins, or more rapid excretion into bile. Articaine; Epinephrine: (Moderate) Coadministration of articaine with oxidizing agents, such as phenobarbital, may increase the risk of developing methemoglobinemia. Efavirenz; Emtricitabine; Tenofovir: (Major) Complex interactions may occur when barbiturates (e.g., phenobarbital) are administered to patients receiving treatment for HIV infection; if treating seizure disorder, a different anticonvulsant should be used whenever possible. Phenobarbital is a strong CYP3A4 inducer and UGT inducer. The effects of aprepitant on tolbutamide were not considered significant. For patients taking estrogens for other indications, like hormone replacement, monitor the patient for signs and symptoms of reduced therapeutic efficacy or need for dosage adjustment. Barbiturates induce CYP3A4. Although this interaction has not been studied by the manufacturer, and published literature suggests the potential for interactions to be low, taking these drugs together may decrease the systemic exposure of terbinafine. Naloxegol is a CYP3A4 substrate; phenobarbital is a strong CYP3A4 inducer. Agents that induce CYP 3A4 may increase the metabolism of vincristine and decrease the efficacy of drug, including barbiturates. Aspirin, ASA: (Moderate) Due to high protein binding, salicylates could be displaced from binding sites, or could displace other highly protein-bound drugs such as barbiturates. Dicyclomine: (Moderate) Dicyclomine can cause drowsiness, so it should be used cautiously in patients receiving CNS depressants like phenobarbital. Eur. Acetaminophen; Dextromethorphan: (Minor) Chronic therapy with barbiturates can increase the metabolism and decrease the effectiveness of acetaminophen. Coadministration with another strong CYP3A inducer decreased suvorexant exposure by 77% to 88%. Prednisolone: (Moderate) Coadministration may result in decreased exposure to prednisolone. An enhanced effect of the displaced drug may occur. Acetazolamide: (Minor) Acetazolamide can induce osteomalacia in patients treated chronically with barbiturates. Phenobarbital is most commonly used to treat seizure disorders including epilepsy in dogs and cats. Dapsone: (Moderate) Monitor for an increase in hemolysis if coadministration of dapsone with phenobarbital is necessary; dapsone efficacy may also be compromised. Potent inducers of CYP3A4, such as the barbiturates, may increase the rate of buspirone metabolism. (Moderate) Additive CNS depression may occur if barbiturates are co-used with sedating antihistamines, such as chlorpheniramine. Tofacitinib: (Major) Coadministration of tofacitinib and phenobarbital is not recommended due to the potential for a loss of response or reduced clinical response to tofacitinib. Coadministration of teniposide and enzyme-inducing antiepileptic drugs resulted in teniposide clearance values that were 2- to 3-times higher than values with teniposide alone. Amlodipine; Telmisartan: (Major) Barbiturates may induce the CYP3A4 metabolism of calcium-channel blockers such as amlodipine, and thereby reduce their oral bioavailability. Anticonvulsant serum concentrations should be monitored closely if these agents are added; the patient should be observed for changes in the clinical efficacy of the antiretroviral or anticonvulsant regimen. If concomitant use is unavoidable, gradually titrate the dose of lapatinib from 1,250 mg per day to 4,500 mg per day in patients receiving concomitant capecitabine (HER2-positive metastatic breast cancer), and from 1,500 mg per day to 5,500 mg per day in patients receiving concomitant aromatase inhibitor therapy (HR-positive, HER2-positive breast cancer) based on tolerability. The remainder of the dose (roughly 75%) is inactivated by the liver, primarily via CYP2C9, with minor metabolism by CYP2C19 and 2E1. Amlodipine; Benazepril: (Major) Barbiturates may induce the CYP3A4 metabolism of calcium-channel blockers such as amlodipine, and thereby reduce their oral bioavailability. If concurrent use is necessary, reduce initial dosage and titrate to clinical response; use the lowest effective doses and minimum treatment durations. Quinine: (Major) If concomitant administration of barbiturates and quinine cannot be avoided, frequently monitor the barbiturate concentration. Concomitant administration of apomorphine and CNS depressants could result in additive depressant effects. Risperidone: (Major) Potent inducers of CYP3A4, such as barbiturates, may decrease plasma concentrations of risperidone and its active metabolite. If the use of both agents is necessary, monitor patients for signs of reduced efficacy. Monitor for decreased response to prednisolone during concurrent use. Armodafinil: (Major) It is not clear how armodafinil interacts with barbiturates like phenobarbital. Coadministration with another strong CYP3A4 inducer decreased tolvaptan exposure by 85%. Barbiturates should be avoided in patients with bronchopneumonia. Estradiol; Progesterone: (Moderate) Barbiturates can accelerate the hepatic clearance of estrogens. Additionally, the amphetamines may delay the intestinal absorption of phenobarbital; the extent of absorption of these seizure medications is not known to be affected. Clindamycin: (Moderate) Concomitant use of clindamycin and phenobarbital may increase clindamycin clearance and result in loss of efficacy of clindamycin. Indinavir: (Major) Barbiturates may increase the metabolism of indinavir and lead to decreased antiretroviral efficacy. Barbiturates induce CYP3A4; hydrocodone is a CYP3A4 substrate. Bosutinib: (Major) Avoid concomitant use of bosutinib, a CYP3A4 substrate, with a strong CYP3A4 inducer such as phenobarbital, as a large decrease in bosutinib plasma exposure may occur. If concurrent use is necessary, reduce initial dosage and titrate to clinical response; use the lowest effective doses and minimum treatment durations. Monitor for reduced efficacy of codeine and signs of opioid withdrawal. Clinicians should note that warfarin doses will require readjustment if a barbiturate is added or discontinued during warfarin therapy. Phenobarbital is a generic name for a type of barbiturate drug. Guaifenesin; Hydrocodone; Pseudoephedrine: (Major) Concomitant use of hydrocodone with barbiturates may cause respiratory depression, hypotension, profound sedation, and death. Dasatinib is a CYP3A4 substrate; phenobarbital is a strong CYP3A4 inducer. Monitor for reduced efficacy of hydrocodone and signs of opioid withdrawal. Luminal/Phenobarbital Sodium Intramuscular Inj Sol: 1mL, 65mg, 130mg Luminal/Phenobarbital Sodium Intravenous Inj Sol: 1mL, 65mg, 130mg Phenobarbital Oral Sol: 5mL, 20mg Phenobarbital Oral Tab: 15mg, 30mg, 60mg, 100mg. (Major) Closely monitor for decreased phenobarbital efficacy during coadministration; clinical monitoring of phenobarbital concentrations with dosage titration if necessary is also warranted. For pediatric patients, concomitant use of maraviroc with a strong CYP3A inducer, without a strong CYP3A inhibitor, is not recommended. In subjects who received ixazomib with another strong CYP3A4 inducer, the ixazomib Cmax and AUC values were decreased by 54% and 74%, respectively. Vorapaxar: (Major) Avoid coadministration of vorapaxar and phenobarbital or primidone. For hormonal contraceptives, this interaction could result in unintended pregnancy or breakthrough bleeding. Monitor patients for sedation or respiratory depression. It is not yet clear what effects CYP450 inducers have on the activation and/or toxicity of cyclophosphamide; the production of active or neurotoxic metabolites may be increased. Additionally, concomitant use of hydrocodone with a barbiturate can decrease hydrocodone concentrations; this may result in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence. 9, Ph. If methemoglobinemia occurs or is suspected, discontinue prilocaine and any other oxidizing agents. Additionally, the amphetamines may delay the intestinal absorption of phenobarbital; the extent of absorption of these seizure medications is not known to be affected. Crizotinib: (Major) Avoid coadministration of crizotinib with phenobarbital due to decreased plasma concentrations of crizotinib, which may result in decreased efficacy. Itraconazole: (Major) Use of barbiturates is not recommended for 2 weeks before or during itraconazole therapy. Educate patients about the risks and symptoms of respiratory depression and sedation. Barbiturates induce CYP3A4 activity and will decrease the plasma concentrations of bicalutamide. Vortioxetine: (Major) Patients should be monitored for a decreased response to vortioxetine when barbiturates are co-administered. Discontinuation of a barbiturate may increase the risk of opioid-related adverse reactions, such as fatal respiratory depression. Barbiturates augment GABA responses by promoting the binding of GABA to the receptor and increasing the length of time that chloride channels are open. Chloramphenicol: (Moderate) Chloramphenicol inhibits the cytochrome P-450 enzyme system and can affect the hepatic metabolism of phenobarbital. How does Phenobarbital work? MMAE is metabolized by CYP3A4; phenobarbital is a strong CYP3A4 inducer. Immediate-release guanfacine may require more frequent dosing to achieve or maintain desired hypotensive response; if it is discontinued, carefully taper the dose to prevent rebound hypertension. A brand name drug in the U.S. is approved by the Food and Drug Administration (FDA), and is supplied by one company - the pharmaceutical manufacturer. Anticoagulants: Phenobarbital lowers the plasma levels of dicumarol (name previously used: bishydorxycoumarin) and causes a decrease in anticoagulant activity as measured by the prothrombin time.Phenobarbital can induce hepatic microsomal enzymes … Mifepristone: (Major) Avoid the use of mifepristone and potent CYP3A inducers such as phenobarbital. (Minor) Bupivacaine is metabolized by CYP3A4. (Moderate) Additive CNS depression may occur if barbiturates are co-used with sedating antihistamines, such as chlorpheniramine. Patients reporting unusual sleep-related behaviors likely should discontinue melatonin use. If saquinavir and barbiturates are used together, the patient must be closely monitored for antiviral efficacy. The clinical significance of this change is not known. Taking these drugs together may significantly decrease velpatasvir plasma concentrations, potentially resulting in loss of antiviral efficacy. Educate patients about the risks and symptoms of respiratory depression and sedation. The relative risk for suicidality was higher in patients with epilepsy compared to those with other conditions; however, the absolute risk differences were similar in trials for epilepsy and psychiatric indications. Coadministration may increase the risk of CNS depressant-related side effects. Fluconazole: (Minor) Barbiturates induce hepatic CYP enzymes including 3A4, 2C19 and 2C9 and may reduce effective serum concentrations of fluconazole. Conjugated Estrogens: (Moderate) Barbiturates can accelerate the hepatic clearance of estrogens. Salsalate: (Moderate) Due to high protein binding, salicylates could be displaced from binding sites, or could displace other highly protein-bound drugs such as barbiturates. This has the effect of elevating seizure threshold and reducing the spread of seizure activity from a seizure focus. Larotrectinib: (Major) Avoid coadministration of larotrectinib with phenobarbital due to decreased larotrectinib exposure and risk of decreased efficacy. If concurrent use is necessary, reduce initial dosage and titrate to clinical response; use the lowest effective doses and minimum treatment durations. (Major) Concomitant use of hydrocodone with barbiturates may cause respiratory depression, hypotension, profound sedation, and death. Pregnancy has been reported during therapy with both estrogen- and/or progestin-based oral contraceptives in patients receiving barbiturates (e.g., phenobarbital). Azelastine; Fluticasone: (Moderate) An enhanced CNS depressant effect may occur when azelastine, an antihistamine, is combined with CNS depressants including the barbiturates. Avatrombopag: (Major) In patients with chronic immune thrombocytopenia (ITP), increase the starting dose of avatrombopag to 40 mg PO once daily when used concomitantly with barbiturates. Barbiturates induce CYP3A4; sufentanil is a CYP3A4 substrate. Sonidegib: (Major) Avoid the concomitant use of sonidegib and phenobarbital; sonidegib exposure may be significantly decreased and its efficacy reduced. Methylphenidate: (Moderate) Psychostimulants, such as methylphenidate, may lower the seizure threshold, thereby reducing the efficacy of anticonvulsants such as phenobarbital. It is recommended to avoid this combination when dihydrocodeine is being used for cough. Emtricitabine; Rilpivirine; Tenofovir alafenamide: (Severe) Concurrent use of phenobarbital and rilpivirine is contraindicated. Levorphanol: (Major) Concomitant use of levorphanol with a barbiturate may cause respiratory depression, hypotension, profound sedation, and death. Raltegravir: (Major) Coadministration of phenobarbital with raltegravir is not recommended. If concurrent use is necessary, reduce initial dosage and titrate to clinical response; use the lowest effective doses and minimum treatment durations. At least a 4-week cessation period is recommended before initiating treatment with doravirine. Metyrapone: (Moderate) Metyrapone may cause dizziness and/or drowsiness. Concurrent use may result in additive CNS depression. Use phenobarbital with caution in patients with low bone density. Mestranol; Norethindrone: (Moderate) Barbiturates can accelerate the hepatic clearance of estrogens. Apixaban: (Major) Avoid the concomitant administration of apixaban and drugs that are both strong inducers of CYP3A4 and P-gp, such as phenobarbital. Coadministration with another strong CYP3A4 inducer is predicted to decrease ivosidenib exposure at steady-state by 33%. Acetaminophen; Oxycodone: (Major) Concomitant use of oxycodone with a barbiturate may cause respiratory depression, hypotension, profound sedation, and death. The hypnotic effects of barbiturates can be reduced by caffeine administration. Acalabrutinib: (Major) Avoid the concomitant use of acalabrutinib and phenobarbital. Trabectedin is a CYP3A substrate and phenobarbital is a strong CYP3A inducer. Concurrent use may result in additive CNS depression. Leucovorin: (Minor) Limited data suggest that leucovorin and levoleucovorin may interfere with the activity of anticonvulsants such as barbiturates. Carbetapentane; Pyrilamine: (Moderate) Drowsiness has been reported during administration of carbetapentane. (Moderate) Additive CNS depression may occur if barbiturates are co-used with sedating antihistamines, such as chlorpheniramine. If concurrent use is necessary, reduce initial dosage and titrate to clinical response; use the lowest effective doses and minimum treatment durations. For patients taking estrogens for other indications, like hormone replacement, monitor the patient for signs and symptoms of reduced therapeutic efficacy or need for dosage adjustment. Phenobarbital induces the CYP3A4 metabolism of elvitegravir. Isoniazid, INH; Rifampin: (Moderate) It may be necessary to adjust the dosage of phenobarbital if given concurrently with rifampin. Barbiturates induce CYP3A4. Monitor for reduced efficacy of codeine and signs of opioid withdrawal. Reduced exposure of valbenazine and its active metabolite may reduce efficacy. In a pharmacokinetic study, felodipine's Cmax was considerably lower in epileptic patients on long-term anticonvulsant therapy than in healthy volunteers. Thyroid hormones: (Minor) Hepatic enzyme-inducing drugs, including barbiturates, can increase the catabolism of thyroid hormones. Chlorpheniramine; Hydrocodone; Phenylephrine: (Major) Concomitant use of hydrocodone with barbiturates may cause respiratory depression, hypotension, profound sedation, and death. rifampicin, phenobarbital) may decrease the serum levels of the active antipsychotic fraction of risperidone. Patients receiving these drugs concurrently should be monitored for possible loss of vincristine efficacy. Galantamine is a substrate for CYP3A4 and CYP2D6. In patients who are tolerating canagliflozin to 200 mg and who require additional glycemic control, the dose may be increased to 300 mg once daily. Educate patients about the risks and symptoms of respiratory depression and sedation. Phenobarbital has a reputation for causing problems with behavior or learning in children. It is used to treat high blood pressure. Pregnancy has been reported during therapy with both estrogen- and/or progestin-based oral contraceptives in patients receiving barbiturates (e.g., phenobarbital). Acetazolamide can also increase the rate of excretion of weakly acidic drugs, such as barbiturates. Oral absorption is delayed by the presence of food. (Moderate) Due to high protein binding, salicylates could be displaced from binding sites, or could displace other highly protein-bound drugs such as barbiturates. During acute overdoses, barbiturates can enhance the formation of toxic acetaminophen metabolites. Use caution during concurrent use of vorapaxar and other barbiturates. Dexmedetomidine: (Moderate) Co-administration of dexmedetomidine with barbiturates is likely to lead to an enhancement of CNS depression. If concurrent use is necessary, reduce initial dosage and titrate to clinical response; use the lowest effective doses and minimum treatment durations. Oral bioavailability is generally good; roughly 70% to 90% of an oral dose of phenobarbital is absorbed from the GI tract. Phenobarbital is a CYP29 and CYP2C19 substrate, and rifampin is an inducer of these enzymes. Dosage reduction may be required for co-use in some patients. Limit the use of opioid pain medications with barbiturates to only patients for whom alternative treatment options are inadequate. Tolcapone: (Moderate) COMT inhibitors, like entacapone or tolcapone, should be given cautiously with other agents that cause CNS depression due to the possibility of additive sedation. Repaglinide: (Major) Coadministration of barbiturates and repaglinide may decrease the serum concentration of repaglinide; if coadministration is necessary, a dose increase of repaglinide may be necessary and increased frequency of blood glucose monitoring. Estazolam is a CYP3A4 substrate. MMAE is a CYP3A4 substrate and phenobarbital is a potent CYP3A4 inducer; therefore, the efficacy of brentuximab may be reduced. For patients regularly taking a barbiturate, an alternative or back-up method of contraception may be advisable to ensure contraceptive reliability during the use of the barbiturate, and for 1 month following the discontinuation of barbiturate use. Phenobarbital is a P-glycoprotein (P-gp) inducer and a strong inducer of CYP3A4; darolutamide is a CYP3A4 substrate. Osimertinib is a CYP3A4 substrate and phenobarbital is a strong CYP3A4 inducer. Riociguat: (Major) Strong inducers of CYP3A (e.g., rifampin, phenytoin, carbamazepine, phenobarbital or St. John's Wort) may significantly reduce riociguat exposure. Venetoclax: (Major) Avoid the concomitant use of venetoclax and phenobarbital; venetoclax levels may be significantly decreased and its efficacy reduced. Consider an alternative anticonvulsant when using elvitegravir. Dextromethorphan; Quinidine: (Major) Quinidine is eliminated primarily via hepatic metabolism, primarily by the CYP3A4 isoenzyme. One study showed that phenobarbital concentrations increased by 51% in adults and 112% in children when valproic acid was added, thus, the age of the patient should be considered when managing this drug interaction. Specific maximum dosage information not available; individualize dosage based on monitoring of serum phenobarbital concentrations and clinical parameters. Discontinuation of a barbiturate may increase the risk of opioid-related adverse reactions, such as fatal respiratory depression. This may reduce effectiveness of the beta blocker. Additionally, concomitant use of hydrocodone with a barbiturate can decrease hydrocodone concentrations; this may result in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence. Limit the use of opioid pain medications with barbiturates to only patients for whom alternative treatment options are inadequate. The development of tolerance indicates that barbiturates should only be considered for short term relief of insomnia or for acute sedation.•Other actions: Because it induces glucuronyl transferase and hepatic bilirubin-binding Y protein, phenobarbital has been used to lower serum bilirubin concentrations in neonates and patients with chronic cholestasis. Phenobarbital also appears to reduce the effects of glutamate and also inhibits neurotransmitter release from nerve terminals, an effect that is mediated by depression of voltage-dependent calcium channels. For patients regularly taking a barbiturate, an alternative or back-up method of contraception may be advisable to ensure contraceptive reliability during the use of the barbiturate, and for 1 month following the discontinuation of barbiturate use. Patients who are taking barbiturates or other sedative/hypnotic drugs should avoid concomitant administration of valerian. Coadministration with another strong CYP3A4 inducer decreased the crizotinib AUC and Cmax at steady state by 84% and 79%, respectively. Taking these drugs together is expected to decrease tenofovir plasma concentrations, which may increase the potential for resistance and HIV treatment failure. Educate patients about the risks and symptoms of respiratory depression and sedation. If concurrent use is necessary, reduce initial dosage and titrate to clinical response; use the lowest effective doses and minimum treatment durations. Treatment cessation. Cobimetinib: (Major) Avoid the concurrent use of cobimetinib with phenobarbital due to decreased cobimetinib efficacy. Strong CYP3A4 inducers can decrease systemic exposure of valbenazine and its active metabolite compared to the use of valbenazine alone. Coadministration with another strong CYP3A4 inducer decreased ribociclib exposure in healthy subjects by 89%. Coadministration with CYP3A4 inducers has not been studied with encorafenib; however, in clinical trials, steady-state encorafenib exposures were lower than encorafenib exposures after the first dose, suggesting CYP3A4 auto-induction.

Rockingham County Nh Sheriff, Héra Et Héphaïstos, Actualité Sur La Bbc Afrique, Canal évasion Nouveauté, La Malédiction Du Pharaon Film Complet,